Navigation Links
New One-Year Data from REMICADE(R) SONIC Trial Show Sustained Efficacy Compared with Azathioprine in Treatment of Crohn's Disease
Date:6/2/2009

ion and complete mucosal healing, the healing of the lining of the bowel, at week 26. Results from the 26 week data showed that 57 percent of patients receiving REMICADE combination therapy and 44 percent receiving REMICADE monotherapy achieved clinical remission without steroids compared with 31 percent of patients receiving azathioprine alone (P < 0.001 REMICADE with azathioprine vs. azathioprine monotherapy; P = 0.009 REMICADE monotherapy vs. azathioprine monotherapy; P = 0.022 REMICADE with azathioprine vs. REMICADE monotherapy). Additionally, mucosal healing was achieved in 44 percent of patients receiving REMICADE combination therapy and 30 percent receiving REMICADE monotherapy achieved mucosal healing compared with 17 percent of patients receiving azathioprine alone (P < 0.001 REMICADE with azathioprine vs. azathioprine monotherapy; P = 0.023 REMICADE monotherapy vs. azathioprine monotherapy; P = 0.055 REMICADE with azathioprine vs. REMICADE monotherapy).

Through the first 26 weeks in SONIC, 24 percent of patients receiving azathioprine monotherapy experienced one or more serious adverse events compared with 16 and 14 percent of patients receiving REMICADE monotherapy and REMICADE with azathioprine, respectively. Two patients receiving azathioprine monotherapy developed colon cancer, one patient receiving azathioprine monotherapy died following a colectomy and one patient receiving REMICADE combination therapy was diagnosed with tuberculosis. Serious infections were reported as follows: 8 in the azathioprine monotherapy group, 4 in the REMICADE monotherapy group and 6 in the REMICADE combination therapy group. There were no deaths, malignancies or reports of tuberculosis during the study extension.

For more information regarding the safety profile for REMICADE, please see "Important Safety Information" below.

About Crohn's Disease


'/>"/>
SOURCE Centocor Ortho Biotech Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9

Related medicine technology :

1. XTENT Announces Positive Two-Year CUSTOM I and One-Year CUSTOM II Trial Data for Novel Drug-Eluting Stent System
2. Abbott Announces Positive One-Year Results from the Worlds First Clinical Trial of a Fully Bioabsorbable Drug Eluting Coronary Stent
3. Results From One-Year Study Suggest Advair(R) Provides Important Benefits for African American Patients With Asthma
4. Data from One-Year Liraglutide Phase 3 Study Published Online in The Lancet
5. New Analysis Shows Efficacy of REMICADE(R) in Treatment of Ulcerative Colitis in Patients with Recent Disease Onset or Long-Standing Disease
6. New Findings Show Efficacy of REMICADE(R) Compared With Azathioprine in Treatment of Crohns Disease According to First-of-its Kind Study
7. Progen Engages Leading CRO to Assist with Phase 3 Trial of PI-88
8. Auxilium Pharmaceuticals, Inc. Receives Clearance to Resume Clinical Trials for XIAFLEX(TM)
9. Romark Initiates Clinical Trial of Alinia(R) for Chronic Hepatitis C in the United States
10. The Multiple Myeloma Research Consortium (MMRC) and Proteolix Initiate Phase 2 Clinical Trial Investigating Carfilzomib for the Treatment of Multiple Myeloma
11. Millennium Initiates Clinical Trial to EVOLVE the Treatment of Patients with Newly Diagnosed Multiple Myeloma
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/15/2014)... , Sept. 15, 2014  Decision Resources ... Physician™ 2014, finds that online information and ... brands to differentiate their offering and support ... device purchasing decisions rely on websites, mobile ... about devices—and these physicians are looking to ...
(Date:9/15/2014)... MINNEAPOLIS , Sept. 15, 2014 ... a non-profit professional association serving more than 4,500 ... released its 2015 SCALENDAR, which chronicles corporate fines ... compliance and ethics professionals have a ready reference ... "We developed the SCALENDAR to help ...
(Date:9/15/2014)... -- Research and Markets has announced the addition ... Tests, 9th Edition" report to their offering. ... testing market and all of its segments, providing customers with ... For Business Planning. This is the ninth edition ... 2013 and early 2014. New entrants, new technologies have entered ...
Breaking Medicine Technology:Physician device decision-makers show strong demand for device manufacturer digital content and support 2Physician device decision-makers show strong demand for device manufacturer digital content and support 3More than $55 billion in fines and settlements added by SCCE to its 2015 Corporate Scandal Calendar 2The Worldwide Market for In Vitro Diagnostic Tests, 9th Edition 2The Worldwide Market for In Vitro Diagnostic Tests, 9th Edition 3
... 2012 Mylan Inc. (Nasdaq: MYL ) today announced its ... Financial Results Adjusted diluted EPS of ... for the same prior year period, an increase of 18%; ... 31, 2011 compared to $1.61 for the prior year, an increase of ...
... CITY, N.J., Feb. 21, 2012 S1 Pharmaceuticals, Inc. ... New Drug (IND) application to the U.S. Food and ... (Lorexys).  Lorexys is the Company,s lead drug candidate for ... Female Sexual Dysfunction (FSD).  Lorexys, clinical ...
Cached Medicine Technology:Mylan Reports Adjusted Diluted EPS of $0.53 for the Quarter, an 18% Increase Over Prior Year Quarter; and $2.04 for the Year, a 27% Increase Over Prior Year 2Mylan Reports Adjusted Diluted EPS of $0.53 for the Quarter, an 18% Increase Over Prior Year Quarter; and $2.04 for the Year, a 27% Increase Over Prior Year 3Mylan Reports Adjusted Diluted EPS of $0.53 for the Quarter, an 18% Increase Over Prior Year Quarter; and $2.04 for the Year, a 27% Increase Over Prior Year 4Mylan Reports Adjusted Diluted EPS of $0.53 for the Quarter, an 18% Increase Over Prior Year Quarter; and $2.04 for the Year, a 27% Increase Over Prior Year 5Mylan Reports Adjusted Diluted EPS of $0.53 for the Quarter, an 18% Increase Over Prior Year Quarter; and $2.04 for the Year, a 27% Increase Over Prior Year 6Mylan Reports Adjusted Diluted EPS of $0.53 for the Quarter, an 18% Increase Over Prior Year Quarter; and $2.04 for the Year, a 27% Increase Over Prior Year 7Mylan Reports Adjusted Diluted EPS of $0.53 for the Quarter, an 18% Increase Over Prior Year Quarter; and $2.04 for the Year, a 27% Increase Over Prior Year 8Mylan Reports Adjusted Diluted EPS of $0.53 for the Quarter, an 18% Increase Over Prior Year Quarter; and $2.04 for the Year, a 27% Increase Over Prior Year 9Mylan Reports Adjusted Diluted EPS of $0.53 for the Quarter, an 18% Increase Over Prior Year Quarter; and $2.04 for the Year, a 27% Increase Over Prior Year 10Mylan Reports Adjusted Diluted EPS of $0.53 for the Quarter, an 18% Increase Over Prior Year Quarter; and $2.04 for the Year, a 27% Increase Over Prior Year 11Mylan Reports Adjusted Diluted EPS of $0.53 for the Quarter, an 18% Increase Over Prior Year Quarter; and $2.04 for the Year, a 27% Increase Over Prior Year 12Mylan Reports Adjusted Diluted EPS of $0.53 for the Quarter, an 18% Increase Over Prior Year Quarter; and $2.04 for the Year, a 27% Increase Over Prior Year 13Mylan Reports Adjusted Diluted EPS of $0.53 for the Quarter, an 18% Increase Over Prior Year Quarter; and $2.04 for the Year, a 27% Increase Over Prior Year 14Mylan Reports Adjusted Diluted EPS of $0.53 for the Quarter, an 18% Increase Over Prior Year Quarter; and $2.04 for the Year, a 27% Increase Over Prior Year 15Mylan Reports Adjusted Diluted EPS of $0.53 for the Quarter, an 18% Increase Over Prior Year Quarter; and $2.04 for the Year, a 27% Increase Over Prior Year 16S1 Pharmaceuticals Announces IND Filing of SIP-104 (Lorexys) for the Treatment of Hypoactive Sexual Desire Disorder (HSDD) 2
(Date:9/16/2014)... 16, 2014 DiaperBuys, a national online ... Aging’ Month this September. Healthy Aging Month was started ... the nation on the positive aspects of growing older. ... conditions or side effects from medications that cause urinary ... Manager for DiaperBuys.com. “This can seem daunting to some ...
(Date:9/16/2014)... 16, 2014 Banish headaches forever with ... approved Cefaly device for chronic migraine relief and treatment. ... the United States. Until now, US patients would directly ... in Belgium and wait 2-3 weeks for their device ... United States and once prescription and payment is received, ...
(Date:9/16/2014)... Reading, MA (PRWEB) September 16, 2014 ... announce its partnership with Fairfax Egg Bank. The collaboration ... and expand the donor egg offering at the Fertility ... operated since 2006 and offers the nation’s largest selection ... is advantageous for several reasons:, , ...
(Date:9/15/2014)... (PRWEB) September 16, 2014 The team ... Carey Danis & Lowe report that the ... was found responsible for the injuries that a woman ... to treat stress urinary incontinence (SUI). , Carey Danis ... medical device litigation and personal injury law. The St. ...
(Date:9/15/2014)... 2014 Hastings and Hastings, an experienced ... announces one flat attorney fee for personal injury cases. ... the largest portion possible of their settlement or recovery ... and damaged personal property. In addition, Hastings and Hastings ... simply states that no fees are due unless a ...
Breaking Medicine News(10 mins):Health News:DiaperBuys Honors ‘Healthy Aging’ Month throughout September 2Health News:DiaperBuys Honors ‘Healthy Aging’ Month throughout September 3Health News:Cefaly Migraine Treatment Device Now Readily Available For Widespread Purchase in United States 2Health News:FCNE Announces Partnership with Fairfax Egg Bank 2Health News:Carey Danis & Lowe Reports On $73 Million Boston Scientific Verdict 2Health News:Hastings And Hastings Announces One Flat Attorney Fee For Personal Injury Cases 2Health News:Hastings And Hastings Announces One Flat Attorney Fee For Personal Injury Cases 3
... , SAN BERNARDINO, Calif., Aug. 11 ... its customers and employees recently raised $266,429.00 to benefit the Leukemia ... has raised over $460,000 for this organization. , , ... the month of June 2009, Stater Bros., customers and employees at ...
... , WASHINGTON, Aug. 11 Even while ... is showing hospitals owned and operated by physicians among the best in the ... of "healthcare reform." , , The independent testing and research ... patients around the country. Overwhelmingly, Cons u mer ...
... Labopharm Inc. (TSX: DDS; NASDAQ: DDSS ) ... the U.S. Food and Drug Administration,s (FDA) complete response ... trazodone. , As previously announced, Labopharm received a complete ... indicating the Company,s new drug application (NDA) for its ...
... public survey conducted in Europe found that the vast ... and prostate cancer screening, according to a new study ... the National Cancer Institute . Gerd Gigerenzer, of ... and colleagues conducted a survey of over 10,200 people ...
... , , , , ... SCOR ), a leader in measuring the digital world, today ... the effects of increasing U.S. unemployment on online consumer activity. While ... substantial declines, there has been a corresponding increase in the number ...
... Healthcare reform has become a hot button issue for politicians and ... clear the air and separate fact from fiction. , , ... e QtY97yVQFUg6so , , ... and unrestricted use at http://www.medi a ...
Cached Medicine News:Health News:Stater Bros. Raises $266,429.00 for the Leukemia & Lymphoma Society 2Health News:Physician Owned and Operated Hospitals Get Top Rankings From Consumer Reports, but They Remain on the Healthcare Reform Chopping Block 2Health News:Physician Owned and Operated Hospitals Get Top Rankings From Consumer Reports, but They Remain on the Healthcare Reform Chopping Block 3Health News:Labopharm submits response to FDA for novel antidepressant 2Health News:Health Insurance Provider Sites Attract Fewer U.S. Visitors as Unemployment Increases 2Health News:Health Insurance Provider Sites Attract Fewer U.S. Visitors as Unemployment Increases 3
... The R4Mplus offers global companies ... help meet RFID compliance initiatives. With ... a variety of connectivity options, and ... is a super value. Plus, the ...
... The 105SL combines enhanced memory, ... rugged and reliable all-metal construction. ... processing and print speed make ... users who value reliability, productivity, ...
... R4Mplus offers global companies a cost-effective ... RFID compliance initiatives. With die-cast metal ... of connectivity options, and complex multi-language ... super value. Plus, the fully integrated ...
... Ideal for patient wristband printing, the ... reliable and accurate scanning for improved patient ... text, and graphics on a variety of ... printer prints patient ID wristbands on demand. ...
Medicine Products: